- Conditions
- Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
- Interventions
- MemoryGel® Breast Implants, MemoryShape® Breast Implants, Other Aesthetic Surgery
- Device · Procedure
- Lead sponsor
- Mentor Worldwide, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2031
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 64 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 1,813
matching trials from the local directory fallback.
- Conditions
- Crohn's Disease, Indeterminate Colitis, Inflammatory Bowel Diseases, Ulcerative Colitis
- Interventions
- Anti TNF therapy including infliximab, No Biologics
- Biological · Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 4,970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2038
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20,167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2030
- U.S. locations
- 167
- States / cities
- Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Dazucorilant, Dazucorilant 150 mg, Dazucorilant 300 mg, Placebo
- Drug · Other
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • San Francisco, California • Neptune City, New Jersey + 1 more
- Conditions
- Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
- Interventions
- Follow-Up, Pharmacotherapy Discontinuation, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 326
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more
- Conditions
- Migraine, Multiple Sclerosis, Small Vessel Ischemic Disease
- Interventions
- Brain Neuroimaging
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 59 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, Cyclosporine, Fludarabine, Melphalan, Methotrexate, Tacrolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
- Conditions
- Bipolar I or II Disorder
- Interventions
- ABBV-932
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Anaheim, California • Colton, California + 41 more
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Abemaciclib, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Luteinizing hormone-releasing hormone (LHRH) agonist, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Acalabrutinib, Ibrutinib, Pirtobrutinib, Zanubrutinib
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 36
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- Avacincaptad pegol (ACP)
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more
- Conditions
- Fallopian Tube Cancer, High Grade Serous Adenocarcinoma of Ovary, Ovarian Cancer, Primary Peritoneal Carcinoma
- Interventions
- ONC-392, Pembrolizumab
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 21
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Danbury, Connecticut + 18 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
- Interventions
- Companion diagnostic ( CDx), Placebo, Tulisokibart
- Diagnostic Test · Drug
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
- Interventions
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
- Other · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 432
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
- Conditions
- Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
- Interventions
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
- Radiation · Other · Biological + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Overweight or Obesity, Psoriatic Arthritis
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
- Conditions
- Advanced Solid Tumor, Hepatocellular Carcinoma
- Interventions
- TORL-4-500
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 5 more
- Conditions
- Myositis
- Interventions
- Glucocorticoids, Nipocalimab, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Fenebrutinib, Placebo, Teriflunomide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
- Conditions
- Autosomal Recessive Stargardt Disease 1 (ABCA4-related), Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Interventions
- ALK-001
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
- Conditions
- Moderate to Severe Crohn's Disease
- Interventions
- AZD7798, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Escondido, California • La Jolla, California + 10 more
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Computed Tomography Scan, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Rochester, Minnesota
- Conditions
- Endometrial Neoplasms
- Interventions
- Brachytherapy, Carboplatin, Cisplatin, Cisplatin (as radiosensitizer), Docetaxel, External Beam Radiotherapy (EBRT), Paclitaxel, Pembrolizumab, Placebo for pembrolizumab
- Radiation · Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more